Pancreatic Cancer Research

ResearcherHospital Universitario Fundación Jiménez DíazActive in the last 2 years

Jesús García‐Foncillas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7591-8006; OpenAlex author ID A5028200237. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 18

  1. Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations. Co-author DOI 10.3389/fphar.2026.1868595↗
  2. The crosstalk within tumor microenvironment and exosomes in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2025.189308↗
  3. FOLFIRINOX Combined with GPX4 Inhibition Induces Ferroptosis and Defines Redox-Based Therapeutic Subgroups in Pancreatic Cancer Co-author DOI 10.1101/2025.09.12.675778↗
  4. Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest. Co-author DOI 10.1002/1878-0261.13616↗
  5. Glutathione Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Cancer Treatment. Co-author DOI 10.3390/antiox13111405↗
  6. DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer. Co-author DOI 10.3390/biomedicines11102812↗
  7. Iron-Dependent Cell Death: A New Treatment Approach against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms241914979↗
  8. A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. Co-author DOI 10.3390/jcm11247310↗
  9. The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. Last author DOI 10.3390/cancers13020322↗
  10. The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. Last author DOI 10.3390/jcm9051252↗
  11. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Last author DOI 10.1007/s12253-017-0341-0↗
  12. The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. Last author DOI 10.3390/jcm8091275↗
  13. New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. Last author DOI 10.3390/ijms19092468↗
  14. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. Last author DOI 10.1371/journal.pone.0182044↗
  15. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. Last author DOI 10.3390/jcm6030029↗
  16. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. First author DOI 10.1155/2016/1869304↗
  17. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? First author DOI 10.1155/2016/4873089↗
  18. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Co-author DOI 10.1007/s12094-014-1177-7↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Javier Martínez‐Useros · 16 shared papers, 2016–2026 · strength 2.79
  2. Michael Ochieng’ Otieno · 5 shared papers, 2023–2025 · strength 1.28
  3. Carlos Lacalle-González · 5 shared papers, 2023–2026 · strength 1.25
  4. María Jesús Fernández‐Aceñero · 7 shared papers, 2017–2025 · strength 0.97
  5. Carlos Lopez-Blazquez · 3 shared papers, 2023–2025 · strength 0.73
  6. Weiyao Li · 7 shared papers, 2017–2022 · strength 0.71
  7. Alberto Orta · 3 shared papers, 2020–2026 · strength 0.58
  8. Nuria Garcia-Carbonero · 4 shared papers, 2018–2022 · strength 0.45
  9. Tomasz Powrózek · 1 shared paper, 2025 · strength 0.37
  10. Paula Iglesias-Matesanz · 1 shared paper, 2024 · strength 0.26
  11. Aiora Cenigaonandia‐Campillo · 1 shared paper, 2024 · strength 0.17
  12. Óscar Aguilera · 1 shared paper, 2024 · strength 0.17
  13. Roberto Pazo-Cid · 1 shared paper, 2022 · strength 0.14
  14. Fernando Rivera · 1 shared paper, 2014 · strength 0.04
  15. Josep M. Tabernero · 1 shared paper, 2014 · strength 0.04
  16. Carles Pericay · 1 shared paper, 2014 · strength 0.04
  17. Berta Laquente · 1 shared paper, 2014 · strength 0.04
  18. Manuel Benavides · 1 shared paper, 2014 · strength 0.04
  19. Alfredo Carrato · 1 shared paper, 2014 · strength 0.04
  20. Javier Gallego-Plazas · 1 shared paper, 2014 · strength 0.04
  21. Enrique Aranda · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.